These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 12582402)

  • 1. A complete and durable response to denileukin diftitox in a patient with mycosis fungoides.
    Carretero-Margolis CD; Fivenson DP
    J Am Acad Dermatol; 2003 Feb; 48(2):275-6. PubMed ID: 12582402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable complete remission of mycosis fungoides following erythroderma induced by denileukin diftitox.
    Kazin R; Bujanauskas P; Vonderheid EC
    J Am Acad Dermatol; 2008 Feb; 58(2 Suppl):S31-2. PubMed ID: 18191695
    [No Abstract]   [Full Text] [Related]  

  • 3. Denileukin diftitox therapy for patients with tumour-stage mycosis fungoides.
    Assaf C
    Dermatol Clin; 2008 Jan; 26 Suppl 1():21-2. PubMed ID: 18405182
    [No Abstract]   [Full Text] [Related]  

  • 4. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides.
    Ghori F; Polder KD; Pinter-Brown LC; Hoff AO; Gagel RF; Sherman SI; Duvic M
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2205-8. PubMed ID: 16595600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome.
    Prince HM; Martin AG; Olsen EA; Fivenson DP; Duvic M
    Leuk Lymphoma; 2013 Jan; 54(1):69-75. PubMed ID: 22738414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene.
    Talpur R; Duvic M
    Clin Lymphoma Myeloma; 2006 May; 6(6):488-92. PubMed ID: 16796781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
    Saleh MN; LeMaistre CF; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Sams MW; Nichols JC
    J Am Acad Dermatol; 1998 Jul; 39(1):63-73. PubMed ID: 9674399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukins in the treatment of mycosis fungoides.
    Gerami P; Guitart J; Rosen S; Kuzel TM
    G Ital Dermatol Venereol; 2008 Feb; 143(1):55-8. PubMed ID: 18833051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia.
    Frankel AE; Surendranathan A; Black JH; White A; Ganjoo K; Cripe LD
    Cancer; 2006 May; 106(10):2158-64. PubMed ID: 16586495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.
    Talpur R; Duvic M
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):180-5. PubMed ID: 22521504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denileukin diftitox plus total skin electron beam radiation in patients with treatment-refractory cutaneous T-cell Lymphoma (mycosis fungoides): report of four cases.
    Buder K; Müller PA; Beckmann G; Ugurel S; Bröcker EB; Becker JC
    Acta Derm Venereol; 2014 Jan; 94(1):94-6. PubMed ID: 23756575
    [No Abstract]   [Full Text] [Related]  

  • 12. Durable complete remission of therapy-refractory, tumor-stage cutaneous T-cell lymphoma under radioimmunotherapy with electron beam irradiation and denileukin diftitox.
    Wobser M; Göppner D; Lang SC; Beckmann G; Flentje M; Ugurel S; Bröcker EB; Becker JC
    Arch Dermatol; 2010 Jul; 146(7):805-6. PubMed ID: 20644054
    [No Abstract]   [Full Text] [Related]  

  • 13. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
    Chin KM; Foss FM
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):199-204. PubMed ID: 17229335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing denileukin diftitox (Ontak) therapy.
    Duvic M; Talpur R
    Future Oncol; 2008 Aug; 4(4):457-69. PubMed ID: 18684057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denileukin diftitox and vision loss.
    Ruddle JB; Prince HM
    Leuk Lymphoma; 2007 Apr; 48(4):655-6. PubMed ID: 17454621
    [No Abstract]   [Full Text] [Related]  

  • 16. Regression of CD30+ cutaneous anaplastic large-cell lymphoma with denileukin diftitox.
    Dao H; Barr PM; Honda K
    J Am Acad Dermatol; 2011 Jun; 64(6):e123-5. PubMed ID: 21571160
    [No Abstract]   [Full Text] [Related]  

  • 17. Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis.
    Avarbock AB; Loren AW; Park JY; Junkins-Hopkins JM; Choi J; Litzky LA; Rook AH
    Am J Hematol; 2008 Jul; 83(7):593-5. PubMed ID: 18335564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy.
    Park M; Liu GT; Piltz-Seymour J; Wisda CL; Rook AH; Junkins-Hopkins JM; Nasta SD; Kim EJ
    Leuk Lymphoma; 2007 Apr; 48(4):808-11. PubMed ID: 17454642
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK).
    Talpur R; Apisarnthanarax N; Ward S; Duvic M
    Leuk Lymphoma; 2002 Jan; 43(1):121-6. PubMed ID: 11908715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
    Dang NH; Pro B; Hagemeister FB; Samaniego F; Jones D; Samuels BI; Rodriguez MA; Goy A; Romaguera JE; McLaughlin P; Tong AT; Turturro F; Walker PL; Fayad L
    Br J Haematol; 2007 Feb; 136(3):439-47. PubMed ID: 17233846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.